F&P Healthcare (FPH) - Competitor Read-Through – Vapotherm 2Q23 Result
Vapotherm (VAPO.NYSE), a small, pureplay competitor to F&P Healthcare’s (FPH) nasal high flow optiflow product Q2 result highlights a modest...
237 Views
IVF: Secular Growth for Decades to Come.
The IVF industry is booming, driven by couples having children later in life as well as infertility problems. There should be plenty of...
313 Views
F&P Healthcare: FY23 Result — Reality Check
F&P Healthcare's (FPH) FY23 result provided a good reality check on trends and outlook in a post COVID-19 world; While lowered near/medium-term...
290 Views
F&P Healthcare (FPH): FY23 Result – Initial Impressions
F&P Healthcare (FPH) reported a FY23 result below our expectations with NPAT of NZ$250m versus our NZ$265m and consensus of NZ$253m; FPH is also...
269 Views
F&P Healthcare (FPH): April Revenue Proxy – Slow Start to FY24
April 2023 respiratory export data shows a slow start to FY24, down -7% YoY (cycling a weak comparable); On a three month rolling basis,...
392 Views